Hester Biosciences Limited has informed the Exchange regarding a press release dated August 01, 2025, titled "20250801 Press Release".
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences reported its Q1 FY26 results, with a mixed picture between standalone and consolidated performance. Standalone revenue from operations fell 14% to INR 634.90 million, dragged by a sharp 33% drop in the Animal Healthcare division (INR 218.22 million) due to delays in government immunisation programmes for PPR and Lumpy Skin Disease, while the Poultry Healthcare division grew 2% to INR 416.52 million. Standalone PAT declined 7% to INR 78.38 million and EBITDA slipped 8% to INR 133.57 million, with margins largely stable. On a consolidated basis, however, revenue rose 2% to INR 841.05 million and PAT surged 131% to INR 172.96 million, driven by a major turnaround at Hester Africa (from a loss of INR 50 million to a profit of INR 55.02 million). Consolidated EBITDA margin expanded sharply from 24% to 31%, reflecting improved cost control and a better mix from international operations.
Investors may view the weak standalone print negatively in the near term, but the strong consolidated recovery—led by Hester Africa's turnaround and expanding margins—offers a positive offset. Management expects the delayed government immunisation orders to come through in subsequent quarters, which could support a rebound in standalone numbers.